Amplia Launches First Stage of Pivotal Narmafotinib Trial
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This study aims to explore a new daily dosing regimen of narmafotinib in combination with standard chemotherapy treatments. Patient enrollment is expected to begin in the fourth quarter of this year, with the study designed to assess safety, tolerability, and efficacy. The trial builds on previous positive data from earlier studies and is intended to support a future registrational submission to the FDA.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
- Amplia and ANZGOG announce Ovarian Cancer Study
- Accent Trial Mature Data Presented at International Conference
- Amplia Therapeutics Halts Recruitment in AMPLICITY Trial
- Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
Later from Amplia Therapeutics
- Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
- Preliminary Final Report and Annual Report YE 31 March 2026
- Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
- Amplia Announces Changes to Board’s Leadership Roles
- Amplia Announces Appointment of Brett Carter to Board
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics